Study finds no support for link between Alzheimer’s disease and PPIs
Researchers conclude that there is no clinically meaningful association between PPI use and risk of Alzheimer’s disease.
Some research has indicated that proton pump inhibitor (PPI) use could increase the risk of dementia.
In a recent study, researchers used national data from Finland to conduct a case-control study of 70,718 people newly diagnosed with Alzheimer’s disease (AD) and 282,858 matched controls.
They found no link between PPI use and risk of AD when they examined a three-year window between exposure and outcome — to reduce the risk of reverse causation (adjusted odds ratio (OR) 1.03, 95% confidence interval (CI) 1.00–1.05). They also found no link between PPI dosage or duration of exposure and AD diagnosis.
Reporting in the American Journal of Gastroenterology (11 July 2017), the team said the results provide no evidence of a clinically meaningful association between PPI use and risk of AD.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20203558
Recommended from Pharmaceutical Press